Rheumatoid Arthritis

There are currently 14 antiviral medications being tested as possible treatments for COVID-19.

Seeing a rheumatologist within 6 weeks did not reduce the severity of radiographic progression.

COVID-19 is being treated with treatments designed for rheumatoid arthritis. They have their pros and cons. Learn more in this article.

David Karp, MD, PhD, president-elect of ACR discusses what an appropriate hydroxychloroquine trial would look like, alternate treatment options, and how rheumatology experts should approach their patients during this time.

Rheumatology patients are more susceptible to infections, making self-quarantining extremely important for this population.

Geeta Nayyar, MD, MBA, discusses how hydroxychloroquine and chloroquine affect patients with arthritis and how it differs for those with coronavirus.

The risk of dying from a cardiovascular event can increase by 50 percent for rheumatoid arthritis patients with low serum folate levels, report researchers in JAMA Open Network.

The findings can lead to new policies, procedures, and programs being implemented at health systems.

Providers who care for patients with asthma or COPD need to be aware of the increased risk of rheumatoid arthritis.

Research from the University of Texas examines how serum folate levels above or below a certain level were linked to an increase in cardiovascular mortality.

The American College of Rheumatology have released guidelines for managing reproductive health that include 131 recommendations and 12 good practice suggestions.

Investigators identified 7 healthcare quality indicators, “the ideal clinical pathway,” for patients with rheumatoid arthritis to reduce the risk of birth complications.

Biologics, JAK inhibitors, and opioid alternatives all served major payoffs in the field in the 2010s.

How therapies are advancing treat-to-target strategies, while the field faces a physician shortage issue.

Sociodemographic, physician, and insurance coverage influences who receives biologic DMARD therapy, findings of a cohort study found.

John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of a pooled safety analysis examining phase 3 studies of filgotinib.

Peter Izmirly, MD, discusses the results of a trial he led examining the possible reduction in recurrence of congenital heart block from treatment with hydroxychloroquine at ACR 2019.

John Sundy, MD, PhD, senior vice president of Inflammation and Respiratory Disease with Gilead Sciences, discusses the results of the 156-week analysis of filgotinib in RA patients.

Martin Bergman, MD, clinical associate professor of Medicine at Drexel University, discusses the results of a study examining prevalence of burnout among rheumatologists.

A new study from ACR 2019 found tocilizumab outperformed rituximab in rheumatoid arthritis patients with low B-cell levels.

Daniel Clauw, MD, of the University of Michigan, discusses how the diagnosis of a rheumatic condition can impact the mental health of patients.